Ben Hendrix

Marks named the specific assumption change (80-85% to 1-for-1 uninsured migration) and walked through the 2H build, including the easier Q4 comparison.

Mike walked through supplemental payment improvement, exchange impact range, and resiliency assumptions, explaining why total guidance was maintained.

Mike provided detailed breakdown of respiratory shortfall and supplemental payment offset, acknowledging results came in slightly below plan.

Mike acknowledged Trump's healthcare plan themes (affordability, transparency, HSAs) but said too early to size impacts. Will update as proposals flow through Congress.

Mike detailed all three programs: Tennessee (largest driver, cash received, accrual began), Texas (grandfathered, 1 month impact in Q3), Kansas (grandfathered, 9 months impact recorded in Q3).

Mike broke out managed care: exchanges up 15.8%, core commercial ex-exchanges up just short of 1%. Sam said healthcare demand appears inelastic, cannot point to consumer confidence as demand driver.

Sam acknowledged recession could ease labor market but said too early to forecast. Confirmed 2025 wage guidance expected to hold.

Sam Hazen discussed enrollment trends and advocacy efforts but acknowledged no current insights on subsidy extension. Mike added exchanges are 7.5% of equivalent admissions and 9% of revenues.

Explained the structure, cost, duration and counterparty benefits, and stated there is no expectation of drawing near to medium term.

Sanjay confirmed Humana membership growth is tailwind across pharmacy (mail order penetration), home solutions (home health and One Home), and primary care. New patient population in line with plan expectations though very early in year. Engagement of new patients tracking in line with expectations.

George confirmed DSNP absolute number higher than expected but percentage slightly lower. Did not gain disproportionate market share from competitor plan exits. DSNP members come in better paneled to value-based partners due to HMO products.

James described broad improvement across HEDIS and patient safety metrics. Confident about trajectory into next year's CAHPS and HOS metrics. George added benefit stability helps CAHPS experience measures.

James acknowledged benefit cut abrasion but said offsetting operational actions working. George cited NPS monitoring showing nothing concerning. Bounce-back membership proves measures working.

James said no meaningful change from prior communication. Exact timing tied to Stars outcome.

George acknowledged D-SNP shortfall but highlighted positive AEP outcomes: higher lifetime value mix, strong value-based partner markets (FL, IL, TX), more competitor switches. Celeste noted 30,000 D-SNP losses were from Medicaid redetermination.

Filton quantified the embedded assumption and described hiring hospital-based physicians and bidding contracts to limit locums exposure.

Filton said effective Q1 decline is 10-12% after premium nonpayment reserves, not just reported 5%. Still expects 25-30% decline for full year as losses steepen. Dynamics around coverage status still unfolding, taking conservative accounting approach.

Miller described two models: step-down (partial hospitalization, IOP under local hospital brands) and step-in (1,000 Branches wellness brand for patients entering system outpatient with IOP, counseling, virtual care). Currently 120 outpatient locations, 10% of behavioral revenue. Payers seeking in-network providers with scale for step-in services.

Filton said surgical volumes turned positive in Q3 after being down in H1, as tough COVID catch-up comparisons are being anniversaried. Case mix up slightly, about 30 basis points, not a significant driver.

Filton attributed the strong pricing to better managed Medicaid contractual rates driven by capacity scarcity, not payer mix. Pricing moderating more slowly than guidance assumed.

Filton clarified the decline is primarily driven by non-recurring prior-period DPP revenues in 2024, not actual program decreases.

Filton explained they moved toward the higher end of the actuarial range for conservatism, hoping to avoid further upticks in 2025.

Steve sees a growing shift among payers toward direct customer acquisition and away from brokers/telebrokers, mirroring auto insurance.

Pat pointed to a strong track record against guidance and guiding on 28 days of actuals, without confirming explicit conservatism.

Pat noted $45M of FTC cash going out near-term and flexibility to invest, reduce debt, or return capital, but gave no firm buyback commitment.

Steve expects more consumer shopping but lighter Medicare Advantage carrier budgets into AEP, with brokers holding up better than carriers.

Steve called it a normal carrier profitability adjustment, too early to gauge AEP impact, and reaffirmed the long-term Medicare Advantage opportunity.

Pat Thompson clarified the high-teens health decline reflects continued under-65 softening on top of ongoing Medicare Advantage headwinds.

Mark detailed CareBridge expansion into additional Medicaid home and community-based programs with early indications of improved cost performance. Aimee Dailey added ER avoidance and PCP visit improvement in duals business.

Pete detailed Carelon's diversified risk approach: category-of-service basis and whole health risk basis with appropriate protections and risk corridors. Good mix of fee and risk business. Newer risk offerings in SMI, oncology, and CareBridge deploying value from cost of care and quality perspective.

Felicia described intentional strategy continuing from 2025 AEP, focusing on deeper performance in larger footprint markets aligned with Medicaid business. Working with exiting members to find appropriate alternative plans.

Mark confirmed lower M&A activity in 2025, focusing on integration. Share repurchases to be more opportunistic with stock below intrinsic value. Long-term 50/50 capital allocation algorithm maintained.

Felicia described accelerated engagement: earlier wellness visits, expedited health risk assessments, and earlier care coordination. Gail added HMO-heavy mix and aggressive value-based care expansion.

Rex confirmed continued commitment to Amedisys acquisition and home-based care as foundational for VBC. Conway emphasized clinical rationale: VBC requires home-based, behavioral, specialty, ambulatory surgical, and serious illness care assets. Nelson added focus on driving productivity and payment yields in services businesses while enabling further growth.

Nelson said encouraged by progress in second half 2024 continuing into 1/1 rate cycle. About 35% of Medicaid revenue renews in 7/1 cycle. Too early to call 7/1 rates but each cycle base data reflects more recent experience. Optimistic gap will continue narrowing.